Outcome MeasureOther

POMS

Profile of Mood States

4 Papers in Blossom

Clinical Thresholds

0200
Low disturbance
Score 0–50
Moderate
Score 51–100
High disturbance
Score 101–200

Outcome Data Across Studies

Reported results for POMS across 2 studies with quantitative data.

Outcome data across 8 study arm–timepoint observations
SD
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
2011Secondary
Psilocybin(experimental)-11211.33.1—
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
2011Secondary
Active Niacin Placebo(active_comparator)-1124.52.0—
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
2011Secondary
Psilocybin(experimental)0.2512———
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
2011Secondary
Psilocybin(experimental)1412——0.060
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation
2021Secondary
Ketamine(experimental)039106.733.2—
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation
2021Secondary
Ketamine(experimental)13950.542.60.002
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation
2021Secondary
Midazolam(active_comparator)039110.638.5—
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation
2021Secondary
Midazolam(active_comparator)13982.945.50.002

Papers Using POMS

Paywallindividual

Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation

This double-blind, parallel-group trial (n=78) compared the effects of intravenous ketamine versus midazolam on neurocognition in depressed patients with significant suicidal ideation. While ketamine rapidly reduced suicidal ideation and improved reaction time and cognitive control, these neurocognitive improvements were independent of changes in depression or mood.

Published
Journal
Journal of Clinical Psychiatry
Authors
Keilp, J. G., Madden, S. P., Marver, J. E., Frawley, A., Burke, A. K., Herzallah, M. M., Gluck, M., Mann, ;. J. J., Grunebaum, M. F.
Open Accessindividual

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

In a randomized, double‑blind, crossover trial of 51 patients with life‑threatening cancer, a single high dose of psilocybin produced large, rapid and sustained reductions in clinician- and self-rated depression and anxiety and increased quality of life, meaning and optimism, with about 80% of participants showing clinically significant improvement at six months. The therapeutic effects were mediated by the intensity of mystical‑type experiences during the session and were corroborated by community observer ratings.

Published
Journal
Journal of Psychopharmacology
Authors
Griffiths, R. R., Johnson, M. W.
Open Accessindividual

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

In a single-group proof-of-concept study of 10 participants with DSM‑IV alcohol dependence, psilocybin administered alongside motivational enhancement therapy produced a significant increase in abstinence after dosing that was largely maintained to 36 weeks, with the intensity of the first session strongly predicting subsequent reductions in drinking, craving and increased abstinence self‑efficacy. There were no significant treatment‑related adverse events, supporting the need for larger controlled trials to evaluate efficacy and mechanisms.

Published
Journal
Journal of Psychopharmacology
Authors
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., Strassman, R. J.
Open Accessindividual

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

This is the first (modern) double-blind placebo-controlled study (n=12) of psilocybin (14mg/70kg) for the treatment of (end-of-life) anxiety (and depression) related to cancer. Treatment led to a significant reduction in anxiety symptoms up to three months after treatment and improvements in depressive symptoms reached significance after six months.

Published
Journal
JAMA Psychiatry
Authors
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R.

Quick Facts

Full Name
Profile of Mood States
Domain
Other
Papers Indexed
4
Score Range
0–200
Interpretation
Lower = better
Unit
points
All Measures